Aker BioMarine will release the fourth quarter 2023 results on Wednesday 14 February 2024 at 07:00 CET.
At 09:00 CET on the same day, the management will host a webcast to present the results. Following a presentation, there will be a Q&A session where written questions can be submitted to ir@akerbiomarine.com.
The webcasted presentation will be in English. To join, please use the link that will be available at www.akerbiomarine.com/investor.
A replay of the presentation and Q&A session will be made available soon after the presentation at the same web page.
For further information, please contact
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820
Email: christopher.vinter@akerbiomarine.com
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.